Infliximab biosimilar use in Crohn's disease will boost the market and help patients, says report

New clinical data will support the use of a biosimilar treatment for Crohn’s disease (CD), and lead to a boost in biosimilar market value, a new report suggests.

In February 2018, 12-month data from the Personalized Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO). The highly anticipated results demonstrated that Celltrion’s (Kosdaq: 068270) CT-P13 (infliximab biosimilar) is comparable to its reference, Johnson & Johnson’s (NYSE: JNJ) Remicade (infliximab), as well as AbbVie’s (NYSE: ABBV) Humira (adalimumab), according to analytics company GlobalData.

Lakshmi Dharmarajan, associate director of immunology at GlobalData, comments: “Given the dearth of head-to-head trial data, this is expected to bolster the use of biosimilars, and lead to cost-effective treatment strategies for patients with CD.”